{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:09:35Z","timestamp":1791155375124,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.ctrv.2006.06.001","type":"journal-article","created":{"date-parts":[[2006,7,25]],"date-time":"2006-07-25T11:57:04Z","timestamp":1153828624000},"page":"445-455","source":"Crossref","is-referenced-by-count":46,"title":["Systemic treatment of AIDS-related Kaposi sarcoma: Current status and perspectives"],"prefix":"10.1016","volume":"32","author":[{"given":"Tazio","family":"Vanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Sprinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Warlet","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo de C.","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedito Antonio L.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Schwartsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2006.06.001_bib1","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/jnci\/92.22.1823","article-title":"Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults","volume":"92","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2006.06.001_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/00002030-200103300-00013","article-title":"Decreasing rates of Kaposi\u2019s sarcoma and non-Hodgkin\u2019s lymphoma in the era of potent combination anti-retroviral therapy","volume":"15","author":"Grulich","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.ctrv.2006.06.001_bib3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0889-8588(03)00048-0","article-title":"Epidemiology of AIDS-related malignancies: an international perspective","volume":"17","author":"Mbulaiteye","year":"2003","journal-title":"Hematol Oncol Clin N Am"},{"issue":"12","key":"10.1016\/j.ctrv.2006.06.001_bib4","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1002\/cncr.20309","article-title":"The changing pattern of Kaposi sarcoma in patients with HIV, 1994\u20132003: the EuroSIDA Study","volume":"100","author":"Mocroft","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2006.06.001_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.jncimonographs.a024250","article-title":"Kaposi\u2019s sarcoma in South Africa","volume":"28","author":"Sitas","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2006.06.001_bib6","first-page":"1585","article-title":"Trends in cancer incidence in Kyadondo County, Uganda, 1960\u20131997","volume":"82","author":"Wabinga","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2006.06.001_bib7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/1097-0142(20000801)89:3<653::AID-CNCR22>3.0.CO;2-Z","article-title":"Cancer incidence in Abidjan, Ivory Coast: first results from the cancer registry, 1995\u20131997","volume":"89","author":"Echimane","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2006.06.001_bib8","first-page":"9","article-title":"Cancer in the African population of Harare, Zimbabwe, 1990\u20131992","volume":"63","author":"Bassett","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2006.06.001_bib9","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1097\/00002030-199912240-00010","article-title":"AIDS-related cancers in Africa: maturation of the epidemic in Uganda","volume":"13","author":"Parkin","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.ctrv.2006.06.001_bib10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0959-8049(01)00109-5","article-title":"Clinical aspects and management of AIDS-related Kaposi\u2019s sarcoma","volume":"37","author":"Levine","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2006.06.001_bib11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0889-8588(03)00043-1","article-title":"Clinical Presentations and standard therapy of AIDS-associated Kaposi\u2019s sarcoma","volume":"17","author":"Von Roenn","year":"2003","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.ctrv.2006.06.001_bib12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(02)00263-3","article-title":"Update on Kaposi\u2019s sarcoma and other HHV8 associated disease. Part 1: epidemiology, environmental predisposition, clinical manifestation, and therapy","volume":"2","author":"Hengge","year":"2002","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.ctrv.2006.06.001_bib13","first-page":"236","article-title":"Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment","volume":"14","author":"Dezube","year":"2004","journal-title":"AIDS Read"},{"key":"10.1016\/j.ctrv.2006.06.001_bib14","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.1989.7.9.1201","article-title":"Kaposi\u2019s sarcoma and the acquired immune deficiency syndrome: a proposal for an uniform evaluation, response and staging criteria","volume":"7","author":"Krown","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib15","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.1997.15.9.3085","article-title":"AIDS-related Kaposi\u2019s sarcoma: prospective validation of the AIDS Clinical Trial Group staging classification","volume":"15","author":"Krown","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00520-002-0363-2","article-title":"Quality of life and Kaposi sarcoma: using preference techniques to value the health gains from treatment","volume":"10","author":"Harris","year":"2002","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2006.06.001_bib17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1081\/CNV-100104284","article-title":"Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi\u2019s sarcoma: a randomized trial of pegylated-lipossomal doxorubicin versus doxorubicin, bleomycin, and vincristine","volume":"19","author":"Osoba","year":"2001","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ctrv.2006.06.001_bib18","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.2003.10.162","article-title":"AIDS-related Kaposi Sarcoma: evaluation of potential new prognostic factors and assessment of AIDS Clinical Trial Group Staging System in the HAAART Era- the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive from Antiretroviral","volume":"21","author":"Nasti","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib19","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.1998.16.7.2445","article-title":"Pegylated-lipossomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi\u2019s sarcoma: results of a randomized phase III clinical trial","volume":"16","author":"Northfelt","year":"1998","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2006.06.001_bib20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1200\/JCO.1997.15.2.653","article-title":"Efficacy of pegylated-lipossomal doxorubicin in the treatment of AIDS-related Kaposi\u2019s sarcoma after failure of standard chemotherapy","volume":"15","author":"Northfelt","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib21","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.1996.14.8.2353","article-title":"Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS related Kaposi\u2019s sarcoma","volume":"14","author":"Gill","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib22","unstructured":"FDA homepage: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/onctools\/organ.cfm. Accessed for the last time in January 31, 2005."},{"key":"10.1016\/j.ctrv.2006.06.001_bib23","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1002\/cncr.11816","article-title":"Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immuno deficiency syndrome-related Kaposi sarcoma","volume":"98","author":"Nasti","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2006.06.001_bib24","first-page":"1717","article-title":"Complete regression of AIDS-related Kaposi\u2019s sarcoma-associated human herpersvirus-8 during therapy with indinavir","volume":"12","author":"Martinelli","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.ctrv.2006.06.001_bib25","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0959-8049(99)00161-6","article-title":"Regression of AIDS-related Kaposi\u2019s sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome","volume":"51","author":"Cattelan","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2006.06.001_bib26","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/00002030-199906180-00026","article-title":"Complete regression of AIDS-related Kaposi\u2019s sarcoma in AIDS","volume":"13","author":"Niehues","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.ctrv.2006.06.001_bib27","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0959-8049(01)00106-X","article-title":"Impact of HAART on the clinical management of AIDS-related cancers","volume":"37","author":"Tirelli","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2006.06.001_bib28","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/00002030-200201250-00029","article-title":"Complete remission of AIDS\/Kaposi\u2019s sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor","volume":"16","author":"Murdaca","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.ctrv.2006.06.001_bib29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00042560-200206010-00015","article-title":"Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone","volume":"30","author":"Paparizos","year":"2002","journal-title":"J Acq Immu Def Synd"},{"key":"10.1016\/j.ctrv.2006.06.001_bib30","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1097\/00002030-199910220-00014","article-title":"Highly active antiretroviral therapy prolongs time to treatment failure in Kaposi\u2019s sarcoma","volume":"13","author":"Bower","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.ctrv.2006.06.001_bib31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1310\/VQXJ-41X6-GJA2-H6AG","article-title":"Effect of protease inhibitors-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi\u2019s sarcoma patients treated with chemotherapy","volume":"4","author":"Leitch","year":"2003","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.ctrv.2006.06.001_bib32","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2001.19.18.3848","article-title":"Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi\u2019s sarcoma treated with chemotherapy","volume":"19","author":"Holkova","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2004.08.064","article-title":"Highly active antiretroviral therapy in AIDS-associated Kaposi\u2019s sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi\u2019s sarcoma","volume":"22","author":"Krown","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib34","doi-asserted-by":"crossref","first-page":"F45","DOI":"10.1097\/00002030-199807000-00002","article-title":"Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV related Kaposi\u2019s sarcoma","volume":"12","author":"Lebbe","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.ctrv.2006.06.001_bib35","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1097\/00002030-200009080-00004","article-title":"Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi\u2019s sarcoma skin lesions from AIDS patients on highly active antiretroviral therapy","volume":"14","author":"Boivin","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.ctrv.2006.06.001_bib36","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1046\/j.0022-202x.2001.01465.x","article-title":"Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi\u2019s sarcoma to highly active antiretroviral therapy","volume":"117","author":"Pellet","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib37","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00126334-200212010-00003","article-title":"Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infections in patients with or without Kaposi sarcoma","volume":"31","author":"Gill","year":"2002","journal-title":"J Acq Immun Def Synd"},{"key":"10.1016\/j.ctrv.2006.06.001_bib38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1470-2045(03)01192-6","article-title":"Use of HIV protease inhibitors to block Kaposi\u2019s sarcoma and tumor growth","volume":"4","author":"Sgadari","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib39","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1182\/blood.V99.10.3771","article-title":"Antitumorigenic effect of HIV protease inhibitors ritonavir: inhibition of Kaposi sarcoma","volume":"99","author":"Pati","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2006.06.001_bib40","unstructured":"US Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. October 29, 2004. Available from: http:\/\/aidsinfo.nih.gov\/guidelines\/."},{"key":"10.1016\/j.ctrv.2006.06.001_bib41","doi-asserted-by":"crossref","unstructured":"BHIV Writing Committee on behalf of the BHIV Executive Committee. Guidelines for the treatment of HIV infected adults with antiretroviral therapy. HIV Med, British HIV Association 2001;2:276\u2013313. Available from: http:\/\/www.aidsmap.com.","DOI":"10.1046\/j.1464-2662.2001.00083.x"},{"issue":"11","key":"10.1016\/j.ctrv.2006.06.001_bib42","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/00002030-200307250-00001","article-title":"A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi\u2019s sarcoma","volume":"17","author":"Postsmouth","year":"2003","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.ctrv.2006.06.001_bib43","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ijc.11648","article-title":"The efficacy of ritonavir in the prevention of AIDS-related Kaposi\u2019s sarcoma","volume":"108","author":"Stebbing","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2006.06.001_bib44","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0305-7372(98)90004-4","article-title":"The systemic treatment of AIDS-related Kaposi\u2019s sarcoma","volume":"24","author":"Schwartsmann","year":"1998","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2006.06.001_bib45","first-page":"185","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Ver"},{"key":"10.1016\/j.ctrv.2006.06.001_bib46","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1200\/JCO.1998.16.2.683","article-title":"Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi\u2019s sarcoma","volume":"16","author":"Stewart","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib47","doi-asserted-by":"crossref","unstructured":"Dedicoat M, Vaithilingum M, Newton R. Treatment of Kaposis sarcoma in HIV-1 infected individuals with emphasis on resource poor settings (Cochrane Review). In: The Cochrane library, Issue 2, 2004. Oxford: Update Software.","DOI":"10.1002\/14651858.CD003256"},{"key":"10.1016\/j.ctrv.2006.06.001_bib48","first-page":"55a","article-title":"Comparison study of liposomal doxorubicin (DOX) alone or with bleomycin and vincristine (DBV) for treatment of advanced AIDS-associated Kaposi\u2019s sarcoma (AIDS\u2013KS): AIDS Clinical Trials Group (ACTG) protocol 286 [abstract]","volume":"16","author":"Mitsuyasu","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib49","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1097\/01.aids.0000131385.60974.b9","article-title":"Pegylated lipossomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi\u2019s sarcoma","volume":"18","author":"Mart\u00edn-Carbonero","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.ctrv.2006.06.001_bib50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00000421-200202000-00012","article-title":"Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma","volume":"25","author":"Rosenthal","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib51","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1200\/JCO.1998.16.10.3369","article-title":"Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi\u2019s sarcoma","volume":"16","author":"Tulpule","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib52","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1200\/JCO.1984.2.10.1115","article-title":"Treatment of epidemic Kaposi\u2019s sarcoma with etoposide or a combination of doxorubicin, bleomycin and vinblastine","volume":"2","author":"Laubenstein","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib53","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00002030-199606001-00009","article-title":"Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated Kaposi\u2019s sarcoma","volume":"10","author":"Girard","year":"1996","journal-title":"AIDS"},{"key":"10.1016\/j.ctrv.2006.06.001_bib54","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4049\/jimmunol.165.1.509","article-title":"Mechanism of paclitaxel activity in Kaposi\u2019s sarcoma","volume":"165","author":"Sgadari","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib55","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.1998.16.3.1112","article-title":"Phase III trial with dose titration of paclitaxel for the therapy of human immuno deficiency virus-associated kaposi\u2019s sarcoma","volume":"16","author":"Welles","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0140-6736(95)92654-2","article-title":"Treatment of HIV associated Kaposi\u2019s sarcoma with paclitaxel","volume":"346","author":"Saville","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2006.06.001_bib57","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.1999.17.6.1876","article-title":"Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi\u2019s sarcoma","volume":"17","author":"Gill","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib58","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cncr.10634","article-title":"Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma","volume":"95","author":"Tulpule","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2006.06.001_bib59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200544020-00001","article-title":"Interactions between antiretroviral drugs and antineoplastic drug therapy","volume":"44","author":"Antoniou","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ctrv.2006.06.001_bib60","unstructured":"WHO essentials drugs list 13th edition, revised in April 2003. Available from WHO homepage: http:\/\/www.who.int\/medicines\/."},{"key":"10.1016\/j.ctrv.2006.06.001_bib61","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0002-9343(91)80081-V","article-title":"Systemic treatment of AIDS-related Kaposi\u2019s sarcoma: results of a randomized trial","volume":"90","author":"Gill","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.ctrv.2006.06.001_bib62","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1200\/JCO.1984.2.10.1115","article-title":"Treatment of epidemic Kaposi\u2019s sarcoma with VP-16 (etoposide) or a combination of doxorubicin, bleomycin and vinblastine","volume":"2","author":"Laubestein","year":"1984","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2006.06.001_bib63","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1200\/JCO.2002.12.038","article-title":"Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi sarcoma: an AIDS Clinical Trials Group clinical study","volume":"20","author":"Evans","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib64","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00000421-200104000-00016","article-title":"Fractionated doses of oral etoposide in the treatment of patients with AIDS-related Kaposi sarcoma","volume":"24","author":"Sprinz","year":"2001","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib65","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1200\/JCO.1997.15.5.2118","article-title":"Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi\u2018s sarcoma (AIDS\u2013KS) with no prior exposure to cytotoxic therapy","volume":"15","author":"Schwartsmann","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib66","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00001622-200109000-00010","article-title":"Management of Kaposi sarcoma: the role of interferon and thalidomide","volume":"13","author":"Krown","year":"2001","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib67","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJM200004063421407","article-title":"Kaposi\u2019s sarcoma","volume":"342","author":"Antman","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2006.06.001_bib68","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/107999002753675712","article-title":"Efficacy of low-dose interferon with antiretroviral therapy in Kaposi\u2019s sarcoma: a randomized phase II AIDS Clinical Trials Group Study","volume":"22","author":"Krown","year":"2002","journal-title":"J Interf Cytok Res"},{"key":"10.1016\/j.ctrv.2006.06.001_bib69","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1470-2045(03)01198-7","article-title":"The treatment of AIDS-related cancers","volume":"4","author":"Levine","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib70","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/A:1008367822016","volume":"10","author":"Sikora","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib71","first-page":"359","article-title":"Treatment of epidemic Kaposi\u2019s sarcoma with a combination of interferon alpha and etoposide","volume":"7","author":"Krigel","year":"1988","journal-title":"J Biol Resp Modif"},{"key":"10.1016\/j.ctrv.2006.06.001_bib72","first-page":"635","article-title":"Combination chemotherapy and a-interferon in the treatment of Kaposi\u2019s sarcoma associated to acquired immune deficiency syndrome","volume":"139","author":"Shepherd","year":"1988","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.ctrv.2006.06.001_bib73","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/030089169608200412","article-title":"Phase II study of Pentosan Polysulfate (PPS) in patients with AIDS-related Kaposi\u2018s sarcoma","volume":"82","author":"Schwartsmann","year":"1996","journal-title":"Tumori"},{"key":"10.1016\/j.ctrv.2006.06.001_bib74","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1200\/JCO.20.1.153","article-title":"Matrix metalloproteinase inhibitors COL-3 in the treatment of AIDS-related Kaposi\u2019s sarcoma: A phase I AIDS Malignancy Consortium Study","volume":"20","author":"Cianfrocca","year":"2002","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2006.06.001_bib75","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1200\/JCO.2005.06.079","article-title":"Imatinib-induced regression of AIDS-related Kaposi\u2019s sarcoma","volume":"23","author":"Koon","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.06.001_bib76","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/infdis\/173.6.1477","article-title":"Use of anti herpes drugs and the risk of Kaposi\u2019s sarcoma: data from the Multicenter AIDS Cohort Study","volume":"173","author":"Glesby","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ctrv.2006.06.001_bib77","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1086\/598351","article-title":"Abatement of cutaneous Kaposi\u2019s sarcoma associated with cidofovir treatment","volume":"26","author":"Hammoud","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ctrv.2006.06.001_bib78","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00002030-200202150-00014","article-title":"AIDS Malignancy Consortium. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi\u2019s sarcoma","volume":"16","author":"Miles","year":"2002","journal-title":"AIDS"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737206001149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737206001149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T07:22:03Z","timestamp":1555744923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737206001149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0305737206001149"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2006.06.001","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}